HistoSonics Showcases Edison Histotripsy System and Clinical Experience at AHPBA

A LinkedIn post from HistoSonics highlights the company’s presence at the AHPBA meeting in Miami Beach, where it is hosting a lunch symposium titled “Histotripsy in Practice: Real-World Experience, Evidence, and Future Frontiers.” The session, scheduled for March 20 from 12:00 p.m. to 12:45 p.m. at the Loews Miami Beach Hotel, features surgical oncology experts from MD Anderson Cancer Center at Cooper and Vanderbilt University.

The post suggests that HistoSonics is positioning its Edison Histotripsy System as a clinically relevant technology transitioning from innovation toward broader implementation, at least within liver applications where use is not restricted to investigations. For investors, this focus on real-world experience and evidence could signal a push to strengthen clinical adoption, differentiate histotripsy from competing ablation modalities, and support future reimbursement and commercialization efforts.

The company also indicates that its team will be available at booth 32/33 on the exhibition floor to discuss the Edison system, underscoring ongoing physician engagement and KOL development in hepatobiliary and pancreatic surgery. While the post notes that use of the Edison System outside liver applications is limited to clinical investigations, the emphasis on “future frontiers” may point to a broader pipeline strategy that, if successful, could expand total addressable market over time.